CERo Therapeutics Holdings Inc
phoenixbiotechacquisitioncorp.comWhat Do They Do?
Develops engineered T-cell therapies for patients with blood cancers and solid tumors.
10-K for FY2025, filed Apr 15, 2026We are an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of…View ↗
On November 14, 2024, we received notice from the FDA that the Investigational New Drug Application (“IND”) was cleared after being put on…View ↗
Based on the preclinical data regarding the use of CER-1236 T cells to combat hematologic malignancies, we began our Phase 1 clinical trial…View ↗
Expand CER-1236 development activities to target solid tumors. We intend to expand the clinical development of CER-1236 to include solid…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Apr 15, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1MView ↗
- ▼ −81% (Loss)
- vs −$5.4M in Q2 FY2025
From blank-check company to cancer therapy developer
The earlier report described a blank-check company seeking a healthcare or life sciences business combination; the latest describes development of engineered T-cell therapies for cancer.
10-K for FY2022, filed Mar 24, 2023 10-K for FY2025, filed Apr 15, 2026We are an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of…View ↗
Who Do They Compete With?
Competes with Adaptimmune Therapeutics, GlaxoSmithKline, MediGene, TCR2 Therapeutics, TScan Therapeutics, Ziopharm Oncology, Adaptive Therapeutics, Immatics, 3T Biosciences, Sana Biotechnology, Gilead Sciences, Bristol-Myers Squibb, Amgen, Nkarta, Allogene Therapeutics, Century Therapeutics, and Fate Therapeutics
10-K for FY2025, filed Apr 15, 2026In addition to the current standard of care treatments for patients with cancer, numerous commercial and academic preclinical studies and…View ↗
Loading...
